Literature DB >> 10555001

Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema.

K Blakolmer1, E C Seaberg, K Batts, L Ferrell, R Markin, R Wiesner, K Detre, A Demetris.   

Abstract

In contrast to all other vascularized organ allografts, chronic rejection (CR) of the liver is potentially reversible. We therefore studied demographic, perioperative, biochemical, and histologic features associated with reversibility or progression to graft failure. Using very stringent clinical and histological criteria, we identified a subgroup of 23 of 916 patients receiving primary liver allografts with CR from the Liver Transplantation Database. Of these, 13 experienced graft failure as a result of CR, and 10 patients recovered to normal histology or liver injury test results. Male-to-female sex mismatch (p = 0.07), younger recipient age (p = 0.09), younger donor age (p = 0.06), white-to-white race match (p = 0.09), primary diagnosis of biliary atresia (p = 0.02), and cold ischemia time of more than 12 hours (p = 0.02) were associated with graft failure. Patients who eventually recovered from CR were more likely to have acute rejection within the first 2 weeks (70% vs 23%; p = 0.04), had a higher number of acute rejection episodes (p = 0.08), and were more likely to have been treated with OKT3 (90% vs 46%, p = 0.07). Although overlap existed in the histopathologic findings between the patients whose grafts failed and those who recovered, those patients who developed bile duct loss in more than 50% of the portal tracts (p < 0.01), severe (bridging) perivenular fibrosis (p = 0.05), and the presence of foam cell clusters (p = 0.06) were more likely to require retransplantation. In contrast to other solid organ allografts, CR of the liver is not an irreversible process. These findings can be used to understand the evolution of CR and to design a biologically correct and clinically relevant staging system.

Entities:  

Mesh:

Year:  1999        PMID: 10555001     DOI: 10.1097/00000478-199911000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  13 in total

Review 1.  Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease.

Authors:  A-J Demetris; John-G Lunz; Susan Specht; Isao Nozaki
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 2.  Functional role of cellular senescence in biliary injury.

Authors:  Luke Meng; Morgan Quezada; Phillip Levine; Yuyan Han; Kelly McDaniel; Tianhao Zhou; Emily Lin; Shannon Glaser; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2015-01-22       Impact factor: 4.307

Review 3.  Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Rinkesh K Bansal; Neeraj Saraf; Dheeraj Gautam; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2017-11-07

4.  Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs.

Authors:  J G Lunz; S Contrucci; K Ruppert; N Murase; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

5.  Muromonab-CD3 for the successful treatment of early chronic rejection after pediatric liver transplantation: report of a case.

Authors:  Tomohide Hori; Justin H Nguyen; Shinji Uemoto
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

6.  Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging.

Authors:  K Blakolmer; A Jain; K Ruppert; E Gray; R Duquesnoy; N Murase; T E Starzl; J J Fung; A J Demetris
Journal:  Transplantation       Date:  2000-06-15       Impact factor: 4.939

7.  Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis.

Authors:  A J Demetris; B Eghtesad; A Marcos; K Ruppert; M A Nalesnik; P Randhawa; T Wu; A Krasinskas; P Fontes; T Cacciarelli; A O Shakil; N Murase; J J Fung; T E Starzl
Journal:  Am J Surg Pathol       Date:  2004-05       Impact factor: 6.394

8.  Histological and Clinicopathological Evaluation of Liver Allograft Biopsy: An Initial Experience of Fifty Six Biopsies.

Authors:  K V Kanodia; A V Vanikar; P R Modi; R D Patel; K S Suthar; L K Nigam; H L Trivedi
Journal:  J Clin Diagn Res       Date:  2015-11-01

9.  Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation.

Authors:  Judith Stift; Hideo A Baba; Elisabeth Huber; Birgit Federmann; Hans-Peter Fischer; Annette Schmitt-Graeff; Herrad Baurmann; Wolfgang Bethge; Peter Schirmacher; Fritz Wrba; Hildegard Greinix; Falko Fend; Rainer Schwerdtfeger; Howard M Shulman; Daniel Wolff; Thomas Longerich
Journal:  Virchows Arch       Date:  2014-01-03       Impact factor: 4.535

10.  Histopathological causes of late liver allograft dysfunction: analysis at a single institution.

Authors:  Eun Shin; Ji Hoon Kim; Eunsil Yu
Journal:  Korean J Pathol       Date:  2013-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.